货号 | AF4985-SP |
别名 | DAP kinase-related apoptosis-inducing protein kinase 1; DRAK1death-associated protein kinase-related 1; EC 2.7.11.1; serine/threonine kinase 17a (apoptosis-inducing); serine/threonine kinase 17a; serine/threonine-protein kinase 17A; STK17A | 全称 | DAP Kinase-related Apoptosis-inducing Protein Kinase 1 |
反应种属 | Human |
应用 | Western Blot(1 µg/mL) |
目标/特异性 | Detects human DRAK1 in direct ELISAs and Western blots. In direct ELISAs, approximately 10% cross‑reactivity with recombinant human DRAK2 is observed. |
使用方法 | Western Blot: 1 µg/mL |
来源 | Reconstitute at 0.2 mg/mL in sterile PBS. |
产品组分 |
供应商 | R&D Systems |
Entrez Gene IDs | 9263 (Human) |
纯化方式 | Antigen Affinity-purified |
免疫原 | E. coli-derived recombinant human DRAK1 Ala115-Glu313 Accession # Q9UEE5 |
生物活性 | Human |
标记 | Unconjugated |
溶解方法 | Reconstitute at 0.2 mg/mL in sterile PBS. |
背景 | DRAK1 (DAP kinase-related apoptosis-inducing protein kinase 1; also STK17A) is a 55 kDa member of the DAP kinase subfamily, CAMK Ser/Thr protein kinase family of enzymes. It is expressed in osteoclasts, resides in the nucleus and initiates apoptosis. Human DRAK1 is 414 amino acids (aa) in length. It contains an N‑terminal polyPro segment (aa 33‑37) followed by a Ser/Thr kinase domain (aa 64‑321) with a catalytic loop (aa 184‑193). Apoptosis apparently requires an intact kinase domain. No rodent DRAK1 has been reported. Over aa 115‑313, human DRAK1 is 95% aa identical to canine DRAK1, and 65% aa identical to human DRAK2. |
运输条件 | Blue Ice |
存放说明 | 4℃ |
参考文献 |
|
Detection of Human DRAK1 by Western Blot. Western blot shows lysates of JEG‑3 human epithelial choriocarcinoma cell line. PVDF membrane was probed with 1 µg/mL of Goat Anti-Human DRAK1 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF4985) followed by HRP-conjugated Anti-Goat IgG Secondary Antibody (Catalog # HAF019). A specific band was detected for DRAK1 at approximately 55 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1. |